-
Moxidectin: A New Logic for Antifungal Synergy
2026-09-11
Moxidectin is best known as a macrocyclic lactone anthelmintic for parasitic worm control, yet new evidence suggests a mechanistically distinct role in antifungal combination therapy. This article examines how moxidectin-driven ergosterol elevation may potentiate polyenes against Candida albicans, translates the findings into a practical validation framework, and outlines the evidence gaps that must be closed before clinical repositioning.
-
IDO1 Blockade and Tumor-Protective JAK2/STAT3
2026-09-10
The reference study shows that pharmacological IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2–STAT3 survival program in tumor cells. Its single-cell analysis explains how this compensatory response may limit IDO1-directed therapy and supports testing combined IDO1 and JAK2/STAT3 pathway inhibition.
-
PTT and CD47 Blockade in Oral Cancer
2026-09-10
The reference study shows that photothermal therapy (PTT) can complement CD47 blockade in oral squamous cell carcinoma by generating a calreticulin-mediated “eat me” signal and reducing extracellular matrix barriers to macrophage access. Its findings support a mechanistically integrated strategy for improving macrophage-mediated tumor clearance, while remaining preclinical and dependent on validated optical and immunological parameters.
-
Phytol C5616 for Reliable Cell Assays
2026-09-09
A scenario-based guide to using Phytol (SKU C5616) in cell viability, proliferation, and cytotoxicity workflows. It explains RXR biology, solvent controls, dose design, assay interpretation, isomer composition, and documentation needed for reproducible experiments.
-
Dihydroethidium: From Signal to Mechanism
2026-09-09
Dihydroethidium (DHE) is more than a red fluorescent superoxide indicator. This article explains how to design, control, and interpret DHE experiments so oxidative stress signals can be connected to mitochondrial injury, apoptosis, and cardiovascular disease mechanisms.
-
Trifluoperazine 2HCl: Assay Design Across Domains
2026-09-08
Trifluoperazine 2HCl is a dopamine D2 receptor inhibitor that can connect receptor pharmacology with immune-cell assays. This guide develops a practical, evidence-aware framework for interpreting dopaminergic signaling, ROS, autophagy, and host-directed antibacterial experiments without overextending the available evidence.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-09-08
MDL 28170 provides a cell-permeable way to interrogate calpain and cathepsin B in neuroprotection research, apoptosis assays, and ischemia-reperfusion injury models. This workflow connects target engagement to structural, biochemical, and functional readouts while highlighting formulation, timing, and selectivity controls.
-
Preeclampsia-Associated UCMSC Senescence and Targets
2026-09-07
A 2025 Placenta study identifies cellular senescence, mitochondrial dysfunction, and cytoskeletal instability as prominent abnormalities in umbilical cord mesenchymal stem cells from preeclamptic pregnancies. Its combination of transcriptomics, functional assays, and dasatinib–quercetin treatment provides a mechanistic framework for evaluating UCMSC quality and senescence-targeted interventions.
-
Tetracycline Workflows for Selection and Assay Control
2026-09-05
Tetracycline combines a well-defined ribosomal mechanism with practical value as an antibiotic selection marker and contamination-control variable. This workflow-focused guide shows how to use it without confusing bacterial selection effects with hepatocyte stress, HMGB1 secretion, or HBV-associated fibrosis biology.
-
Forskolin Workflows for cAMP and Cell Assays
2026-09-05
Forskolin provides a direct, controllable way to elevate intracellular cAMP in stem-cell, neuroendocrine, inflammatory, and epithelial assay systems. This guide translates its adenylate cyclase activity into practical workflows, including CFTR trafficking experiments inspired by a recent epithelial-cell study, while separating established evidence from exploratory applications.
-
Annexin V-PE Reagent for CAR-T Cell Death Assays
2026-09-04
Annexin V-PE Reagent provides a rapid phosphatidylserine-based readout for distinguishing early apoptotic responses from broader CAR-T-associated cell death. Its one-step staining workflow complements structural studies of CD38 CAR binders by connecting affinity engineering with measurable target-cell killing and fratricide.
-
Entecavir: Potency, Resistance, and Platelet Safety
2026-09-04
Entecavir (BMS200475) is more than a nanomolar HBV polymerase inhibitor. This evidence-focused guide connects mechanism, resistance modeling, cccDNA interpretation, and a rare delayed thrombocytopenia signal to improve translational assay design.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-09-03
Hydroxychloroquine Sulfate provides an aqueous-compatible research reagent for probing autophagy pathway modulation and TLR7/9-dependent immune signaling in autoimmune disease research. It is best suited to freshly prepared, short-term workflows and should be avoided when protocols require DMSO or ethanol solubility or long-term solution storage.
-
EZ Cap™ Cre mRNA (m1Ψ): Assay Design
2026-09-03
Learn how EZ Cap™ Cre mRNA (m1Ψ) can serve as a mechanistically resolved assay payload for evaluating mRNA delivery, translation, nuclear access, and loxP recombination. This guide connects Cre biology with emerging extrahepatic delivery platforms while defining practical controls and handling considerations.
-
PTT and CD47 Blockade in Oral Squamous Cell Carcinoma
2026-09-02
A 2026 study shows that photothermal therapy (PTT) can strengthen CD47 blockade in oral squamous cell carcinoma by generating a calreticulin-dependent “eat me” signal and improving macrophage access through extracellular matrix remodeling. The findings support a dual-barrier strategy for solid-tumor immunotherapy, while also clarifying which experimental readouts are needed to distinguish immune activation from nonspecific thermal injury.